Immune control of tumor stemness and therapy resistance
Cancer stem cells (CSC) are a small group of tumor cells capable of self-renewing, giving rise to new tumors, and resisting treatment, thereby causing recurrence and metastasis and representing a serious clinical problem. However, there are no approved therapies for their elimination, and limited information is available on the effects of current therapies on tumor stemness. A general consensus suggests that the anti-inflammatory and immunosuppressive tumor microenvironment promotes tumor stemness. Since we previously reported that ablation of the p50 NF-κB gene in the hematopoietic compartment (p50fl/flTie2-Cre mice) restores M1/Th1 antitumor immunity, we studied its effects on CSC and therapy resistance in models of fibrosarcoma and melanoma. Using p50fl/flTie2-Cre mice, we demonstrate that p50 NF-κB silencing impairs CSC development, their migratory capacity, and epithelial-mesenchymal transition (EMT), events known to correlate with tumor aggressiveness. Furthermore, we identify a clear antagonistic effect between Th1 and Th2 T cell polarization, with the former acting as inhibitors and the latter promoting the stemness phenotype. Consistently, while immunotherapy with anti-PD-1 promoted a marked reduction in CSC and tumor development, associated with increased levels of IFNγ, whereas concomitant administration of anti-IFNγ antibodies restored tumor growth and dissemination. Moreover, treatment with anti-IL-4 enhanced the antitumor effects of immunotherapy, reducing tumor cell stemness. Importantly, the antitumor effects of high-dose IFNγ and anti-IL-4 were confirmed in combination with doxorubicin chemotherapy. Overall, our data indicate that shifting the immune response toward a robust M1/Th1 state can significantly improve current immunotherapies and chemotherapies, by limiting CSC properties.
Authors
- Giovanna Chiorino (ORCID: https://orcid.org/0000-0002-9502-6400)
- Paola Ostano (ORCID: https://orcid.org/0000-0002-4000-2954)
- G Ballerini (ORCID: https://orcid.org/0009-0007-9753-5704)
- Antonio Sica (ORCID: https://orcid.org/0000-0002-8342-7442)
- Anna Pastò (ORCID: https://orcid.org/0000-0002-5783-0668)
- Francesca Guana (ORCID: https://orcid.org/0000-0001-9358-5949)
- Francesca Maria Consonni (ORCID: https://orcid.org/0000-0001-5229-0263)
- Marina Sironi (ORCID: https://orcid.org/0000-0002-3342-1149)
- Mariangela Storto
- Martina Incerti (ORCID: https://orcid.org/0000-0002-4550-0020)
- Alberto Amadori (ORCID: https://orcid.org/0000-0001-8821-5812)
Institutions
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- University of Padua (IT)
- Fondazione Edo ed Elvo Tempia (IT)
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Cancer Immunology Research
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1158/2326-6066.cir-26-0211
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00